 Insmed Incorporated Nasdaq:INSM, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that new data from the Phase 2 WILLOW study of brensocatib formerly known as INS1007 in non-cystic fibrosis bronchiectasis NCFBE will be presented during a virtual clinical trials session hosted by the American Thoracic Society ATS on Wednesday, June 24, 2020, at 2:00 pm ET. Data will be presented by lead study investigator James Chalmers, MBChB, Ph.D., Professor and Consultant Respiratory Physician at the School of Medicine, University of Dundee, UK. Insmed will hold a conference call following the oral session during which Professor Chalmers will further discuss the WILLOW data and Insmed management will provide a business assessment of brensocatib. 